Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials

Documenti analoghi

• Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials
  di: April W. Armstrong, et al.
  Pubblicazione: (2025-03-01)
• Deucravacitinib in Plaque Psoriasis After Inadequate Response to Apremilast: Phase 3 POETYK Analysis
  di: April W. Armstrong, et al.
  Pubblicazione: (2025-12-01)
• Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc Analysis
  di: April W. Armstrong, et al.
  Pubblicazione: (2024-06-01)
• Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials
  di: Neil J. Korman, et al.
  Pubblicazione: (2024-12-01)
• Short-Term Effectiveness and Safety of Deucravacitinib in Psoriasis: A Multicenter Real-World Study with Scalp-Specific Outcomes—IL PSO (Italian Landscape Psoriasis)
  di: Luciano Ibba, et al.
  Pubblicazione: (2026-03-01)